CDMO Companies in India: Jubilant Pharmova vs Windlas Biotech — Who has an edge

CDMO Companies in India

India’s Contract Development and Manufacturing Organisation (CDMO) space has become one of the most closely watched corners of the pharma sector, riding two structural tailwinds simultaneously: global innovator pharma companies looking to de-risk supply chains away from China (“China Plus One” and “friendshoring”), and a widening demand-supply gap in complex manufacturing categories like sterile injectables and radiopharmaceuticals. Within this landscape, Jubilant Pharmova and Windlas Biotech represent two very different scales and models of the same broad theme — one a diversified, globally-integrated specialty pharma major with CDMO as one of six business lines, the other a focused, founder-led domestic generics CDMO that has just completed 25 years in the business.

This article will discuss these two companies on the specific lenses that matter most to investors and industry-watchers. We will discuss on export order book strength, position in the largest CDMO categories, place in the pharma supply chain, and order-book visibility/revenue predictability — along with the underlying financials.

CDMO Companies – Jubilant Pharmova VS Windlas Biotech

Parameter	Jubilant Pharmova	Windlas Biotech
Business model	Diversified specialty pharma: Radiopharma, Radiopharmacy, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO (Drug Discovery + API), Generics, Proprietary Novel Drugs	Pure-play generic formulations CDMO with three verticals: CDMO, Trade Generics & Institutional, Exports
Q1’FY27 / FY26 Revenue	₹2,229 Cr (Q1’FY27, +17% YoY)	₹904 Cr / ₹9,041 Mn (FY26, +19% YoY)
Scale of operations	Global — US, Canada, India, Europe; 5,500 employees	India-based (Dehradun); 1,385 employees
Manufacturing footprint	6 manufacturing + 3 research facilities + 45 radiopharmacies	5 WHO-GMP plants in Dehradun + 1 under construction (Plant 6)
Vision target	2x revenue (₹13,500 Cr) by FY30, 23-25% EBITDA margin, zero net debt	18% 5-yr revenue CAGR track record; continuing multi-vertical scale-up
Net debt position	Net debt/EBITDA 1.8x (June 2026)	Net debt-free, ₹2,507 Mn net liquidity

Jubilant Pharmova operates roughly 25x the revenue scale of Windlas, and CDMO Sterile Injectables is only one of six segments (22% of Q1’FY27 revenue), whereas for Windlas, CDMO is the core identity of the company (73% of FY26 revenue).

Also Read “Best 5 CDMO pharma companies in India”

Export Order Book & International Reach: Jubilant Pharmova VS Windlas Biotech

Jubilant Pharmova is structurally export-heavy — 95% of its revenue is USD-denominated and 81% comes from the USA, with the CDMO Sterile Injectables business built almost entirely to serve US innovator pharma companies out of its Spokane (Washington) and Montreal (Canada) facilities. Its CDMO-SI order book is anchored in long-duration contracts:

• 5 of the top 20 global pharma companies are customers
• 25+ customers with patent-protected, limited-competition products
• 5+ years average relationship tenure with top 10 customers
• 90%+ repeat customer business
• ~24-month switching timeline for customers (a natural moat)
• Onboarded one of the world’s largest oncology products onto Line 3

Windlas Biotech’s export vertical is much smaller in absolute terms but is scaling quickly off a low base:

Windlas Exports	FY24	FY25	FY26
Revenue (₹ Mn)	274	326	458
YoY Growth	—	+19%	+40%
Countries	—	10	10
Products exported	74	80	67
Share of total revenue	—	4%	5%

Windlas describes FY26 exports growth as “an encouraging validation of efforts towards regulatory approvals and product registrations over the past few years,” but exports remain just 5% of its total revenue mix, focused on emerging and semi-regulated markets rather than the US/EU. This is the starkest divergence between the two companies: Jubilant Pharmova’s entire CDMO-SI and Radiopharma businesses are the export book (largely US-regulated market), while Windlas’s export vertical is a small, still-developing satellite to a predominantly domestic CDMO business.

Jubilant Pharmova has a structurally larger, more mature, and higher-value (regulated-market) export book; Windlas has a smaller but fast-growing export engine still in early innings.

Position Among India’s Largest CDMO Companies in India

Both companies claim leadership positions, but in different categories of “largest.”

Jubilant Pharmova positions itself as:

• The leading contract manufacturer of Radiopharmaceuticals in North America, with the 2nd largest radiopharmacy network in the US (45 radiopharmacies vs. market leader Cardinal Health’s 160+)
• A leading North American CDMO for Sterile Injectables, with a demand-supply gap in the global CDMO-SI market projected to widen to 700 Mn vials by 2027 (global CDMO-SI market growing at ~11% CAGR from USD 13 Bn in 2023 to USD 20 Bn in 2027)
• An Indian leader in Integrated Drug Discovery services (CRDMO), with 100+ programs delivered and strategic partnerships with large pharma (e.g., Pierre Fabre for biologics/ADCs)

Windlas Biotech positions itself as:

• “Among India’s leading Contract Development and Manufacturing Companies” specifically for the generic formulations value chain — i.e., domestic oral solids/liquids/injectables CDMO for Indian pharma majors
• Serves 926 CDMO customers, including 8 of the top 10 Indian pharmaceutical companies — a claim to being deeply embedded with India’s largest branded generics players, even if Windlas itself is a mid-cap
• Complex generics now form 74% of its CDMO product mix (up from 67% a year earlier), reflecting a shift toward higher-value, harder-to-replicate formulations (modified-release, FDCs, novel dosage forms)

These are different “largest” claims entirely. Jubilant Pharmova claims scale leadership in global, regulated-market, technology-intensive CDMO categories (radiopharma, sterile injectables). Windlas claims relationship leadership in India’s domestic generic formulations CDMO market, serving the country’s biggest branded generics companies as an outsourced manufacturing partner.

Position in the CDMO Pharma Supply Chain

Contract Development and Manufacturing Companies	Jubilant Pharmova	Windlas Biotech
Upstream (API/discovery)	Full integration — in-house Drug Discovery (Bengaluru, Delhi NCR, France) + CDMO API (Nanjangud) with 900+ MT capacity	No API/discovery layer; sources APIs externally (flagged as “Supplier Risk” — API price volatility)
Mid-stream (formulation/fill-finish)	CDMO Sterile Injectables (Spokane, Montreal) — Fill & Finish for innovator pharma; Radiopharmaceutical GMP manufacturing	Core strength — 5 WHO-GMP plants covering oral solids, liquids, injectables (ampoules, vials, lyophilized)
Downstream (distribution/dispensing)	Owns forward integration into radiopharmacies (45 pharmacies, ~400-vehicle fleet, servicing 1,800 hospitals)	Owns Trade Generics & Institutional distribution (1,582 stockists/distributors across 29 states)
End-market	US/global innovator pharma (B2B), hospitals (B2B2C via radiopharmacies)	Indian pharma majors (B2B, CDMO), rural/semi-urban India (B2B2C via Trade Generics), overseas registrations (Exports)

An important nuance: Jubilant Pharmova has built a genuinely vertically integrated model — from drug discovery and API through to fill-finish manufacturing and, in Radiopharma, all the way to last-mile pharmacy delivery. Management explicitly frames this forward integration as a barrier to entry (“Forward integration with radiopharmacies helps gain market share”).

Windlas, similarly, has built vertical integration on the domestic side — from formulation R&D and IP-owned product development through manufacturing to its own Trade Generics distribution network — but does not participate in upstream API/discovery, relying instead on a diversified, dual-sourced supplier base to manage input risk.

Both companies pursue vertical integration as a competitive moat, but at different points of the value chain and geographic scope — Jubilant Pharmova end-to-end globally in specialty/complex categories; Windlas end-to-end domestically in generic formulations.

Order Book Visibility / Revenue Predictability Jubilant Pharmova VS Windlas Biotech

This is arguably the most decision-relevant comparison for investors, and the two CDMO companies differ meaningfully in how their revenue visibility is constructed.

Jubilant Pharmova

• CDMO-SI contracts are typically 3+ years with auto-renewal, and technology transfer to a new CDMO takes customers 18–24 months — creating high switching costs and multi-year revenue lock-in once a line is qualified
• However, near-term visibility has been volatile: Q1’FY27 consolidated EBITDA fell 11% YoY (margin down 385 bps to 11.9%) due to unavailability of high-margin SPECT products (remediation work ongoing at CMO Montreal) and negligible third-party CDMO-SI revenues
• New capacity (Lines 3, 4, 5 at Spokane/Montreal) provides medium-term revenue visibility — Line 3 commercial batch production is only just starting in FY27, with peak revenue potential of USD 80-90 Mn per line reached over ~3.5 years
• Radiopharma’s growth (Ruby-Fill® up 26% annualized) is running ahead of new PET/SPECT product launches (targeting incremental TAM of USD 535 Mn by FY29), so visibility is a blend of installed-base annuity revenue and lumpy new-product/line ramp-ups

Windlas Biotech

• Top-10 customer concentration has structurally declined from 52% (FY22) to 32% (FY26) — a genuine derisking of revenue base that improves the quality (not just quantity) of predictability
• 13 consecutive quarters of record revenue — management’s chosen proof point of consistency
• CDMO customer count has grown from ~285 (FY22 implied) to 926 in FY26, roughly compounding at a third annually
• No explicit multi-year contract disclosure (unlike Jubilant’s stated 3-year CDMO-SI norm), but the combination of broad-based customer growth, rising complex-generics mix (stickier, harder-to-switch formulations), and consistent quarterly delivery suggests a more granular, less lumpy revenue base
• Net debt-free balance sheet (₹2,507 Mn net liquidity) reduces financing-related earnings volatility that can affect predictability of reported profits

Revenue predictability Jubilant Pharmova VS Windlas Biotech	Jubilant Pharmova	Windlas Biotech
Contract tenure	3+ yrs, auto-renewing (CDMO-SI)	Not separately disclosed
Customer switching cost	High (18-24 month tech transfer)	High for complex generics; IP-owned formulations create stickiness
Revenue concentration	Not disclosed at customer level	Top-10 concentration down to 32% (from 52%)
Recent volatility	High — Q1’FY27 EBITDA margin down 385 bps YoY	Low — 13 straight quarters of record revenue
New capacity ramp risk	High — Lines 3/4/5 still ramping to peak utilization over 3.5 yrs each	Moderate — Plant 6 (Selaqui) commercialization targeted H1 FY27

Windlas currently offers more consistent, broad-based revenue delivery (13 consecutive record quarters, declining customer concentration), while Jubilant Pharmova offers higher long-run contract lock-in and switching costs once a CDMO-SI line is qualified, but near-term earnings have shown more volatility as new capacity ramps and legacy SPECT supply normalizes.

Financials of these CDMO Companies

Metric	Jubilant Pharmova (Q1’FY27, ₹ Cr)	Windlas Biotech (FY26, ₹ Cr, converted from ₹ Mn)
Revenue	2,229 (+17% YoY)	~904 (+19% YoY)
EBITDA Margin	11.9% (down 385 bps YoY)	~13.4% adjusted (up from 12.7%)
Net Debt/EBITDA	1.8x	Net debt-free
ROCE	~11% (TTM, ex-CWIP basis)	32% (ex-CWIP)
Business mix skew	CDMO-SI is 22% of revenue; Radiopharma is 46%	CDMO is 73% of revenue

Note: Jubilant Pharmova figures are quarterly (Q1’FY27); Windlas figures are full-year (FY26) — direct comparison should account for this difference in reporting period, but the ROCE gap is directionally telling: Windlas’s smaller, asset-light-relative-to-revenue, domestically-focused CDMO model is currently generating materially higher capital efficiency than Jubilant Pharmova’s capital-intensive, multi-line-ramping global CDMO-SI/Radiopharma build-out.

Key Takeaways for Best CDMO stock​

1. Scale and market: Jubilant Pharmova is a global, US-dollar-earning specialty pharma conglomerate with CDMO as one of several high-growth engines; Windlas Biotech is a focused, India-domestic generic formulations CDMO with exports as an emerging, still-small vertical.
2. Export order book: Jubilant Pharmova’s export exposure (95% USD revenue) dwarfs Windlas’s (5% of revenue), but Windlas’s 40% YoY export growth in FY26 signals a credible, if early-stage, international ramp.
3. “Largest CDMO Companies” claims are not directly comparable: Jubilant Pharmova claims leadership in regulated-market radiopharma and sterile injectables; Windlas claims leadership/deep relationships in India’s domestic generic formulations CDMO space, serving 8 of India’s top 10 pharma companies.
4. Supply chain integration: Both are vertically integrated — Jubilant Pharmova globally across discovery-to-dispensing in specialty categories; Windlas domestically across formulation-to-distribution in generics.
5. Revenue predictability: Windlas currently shows steadier, more granular growth (declining customer concentration, 13 consecutive record quarters); Jubilant Pharmova offers structurally longer contract lock-ins but has faced more near-term earnings volatility as new global capacity ramps.

For investors, the choice between the two is less “which is the best CDMO stock” and more a question of risk appetite and exposure preference: Jubilant Pharmova offers exposure to high-growth, high-barrier global specialty categories (radiopharma, sterile injectables) with capital-intensive ramp-up risk, while Windlas Biotech offers a lower-risk, high-ROCE, domestically-anchored generics CDMO companies story with an export option still in its early innings.